A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab

Purpose We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients. Patients and methods TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with b...

Full description

Bibliographic Details
Published in:	Molecular Oncology
Main Authors:	Josie Hayes, Helene Thygesen, Walter Gregory, David R. Westhead, Pim J. French, Martin J. Van Den Bent, Sean E. Lawler, Susan C. Short
Format:	Article
Language:	English
Published:	Wiley 2016-10-01
Subjects:	microRNA Glioblastoma Bevacizumab Glioma Prediction
Online Access:	https://doi.org/10.1016/j.molonc.2016.06.004

Similar Items

The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis
by: Alejandro Bruna-Mejías, et al.
Published: (2025-05-01)

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
by: Alissa Thomas, et al.
Published: (2018-01-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
by: Liang Yen Liu, et al.
Published: (2019-06-01)

Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment?
by: Murat Baloglu, et al.
Published: (2025-05-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
by: Masahiro Nishikawa, et al.
Published: (2021-03-01)

Advanced Targeted Therapeutic Strategies for Glioblastoma Multiforme: Bevacizumab and Its Emerging Nanotechnology-Based Interventions
by: Soner Şahin, et al.
Published: (2024-12-01)

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma
by: Thomas Simon, et al.
Published: (2018-08-01)

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
by: Saket Jain, et al.
Published: (2022-01-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
by: Emil Lou, et al.
Published: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
by: Seung Won Choi, et al.
Published: (2018-05-01)

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
by: Christophe Lallemand, et al.
Published: (2020-10-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
by: Minjie Fu, et al.
Published: (2023-06-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
by: George Ansstas, et al.
Published: (2016-01-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
by: Lei She, et al.
Published: (2022-08-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
by: Samy Ammari, et al.
Published: (2021-07-01)

MicroRNAs in high-grade gliomas: What is their role?
by: Stepanović Aleksandar, et al.
Published: (2023-01-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
by: Patrick Roth, et al.
Published: (2020-06-01)

Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy
by: Pei Xun, et al.
Published: (2025-12-01)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2020-12-01)

TREATMENT FOR RECURRENT GLIOBLASTOMA: ARE THERE SUCCESSES?
by: G. I. Kobyakov, et al.
Published: (2015-04-01)

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials
by: Chen Z, et al.
Published: (2018-07-01)

The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report
by: Wangyan Zhong, et al.
Published: (2024-09-01)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
by: Jack Patrick Gleeson, et al.
Published: (2020-01-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)

Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently?
by: Zhizhao Qu, et al.
Published: (2025-05-01)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
by: Thomas Urup, et al.
Published: (2020-05-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
by: Amy eBarone, et al.
Published: (2013-04-01)

Bevacizumab in recurrent WHO grades II–III glioma
by: Soufyan Annakib, et al.
Published: (2023-07-01)

Relation of oncogenic microRNA-10b and microRNA-21 to glioblastoma size and localization
by: Nikitović Marina, et al.
Published: (2025-01-01)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
by: Gang Yang, et al.
Published: (2022-08-01)

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
by: Richard E. Kast
Published: (2018-09-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
by: Zhaoyan Chen, et al.
Published: (2024-05-01)

Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model
by: Thi-Anh-Thuy Tran, et al.
Published: (2023-01-01)

Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment
by: Chiung-Chyi Shen, et al.
Published: (2020-07-01)

The potential of miRNA-based approaches in glioblastoma: An update in current advances and future perspectives
by: Edgar G. Ordóñez-Rubiano, MD, PhD (c), et al.
Published: (2024-01-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
by: Oguz Ozel, et al.
Published: (2016-08-01)

Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma
by: Chengrui Yan, et al.
Published: (2025-09-01)

Small cell glioblastoma: A glioblastoma subtype with an unexpected response
by: Ionela Bizu, et al.
Published: (2019-06-01)

Tectal glioblastoma Glioblastoma tetal
by: Feres Chaddad Neto, et al.
Published: (2007-12-01)